{
  "url": "https://www.law.cornell.edu/regulations/new-york/8-NYCRR-66.5",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 8 § 66.5 - [Effective until 8/7/2025] Use of therapeutic pharmaceutical agents",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 8 § 66.5 - [Effective until 8/7/2025] Use of therapeutic pharmaceutical agents\n\nState Regulations\n(a) Definitions. As used in this section: (1)\n\nTopical therapeutic pharmaceutical\nagents\nshall mean those drugs identified in paragraph (e) of\nsubdivision (1) of section\n7101-a\nof the\n\nEducation Law, which shall be limited to topical application to the surface of\nthe eye for therapeutic purposes or nasal sprays for the treatment of dry eye\ndisease identified in subparagraph (iii) of paragraph (f) of section\n7101-a\nof the\n\nEducation Law.a\n(2)\n\nTopical\ntherapeutic pharmaceutical agents for the treatment of glaucoma and ocular\nhypertension\nshall mean: (i) those\ndrugs identified in paragraph (f) of subdivision (1) of section\n7101-a\nof the\n\nEducation Law. (3)\n\nOral therapeutic pharmaceutical agents solely for the treatment of\ndiseases of the eye and adnexa\nshall mean those drugs identified in\nparagraph (g) of subdivision (1) of section\n7101-a\nof the\n\nEducation Law. (4)\n\nAcceptable accrediting agency\nshall mean an organization\naccepted by the department as a reliable authority for the purpose of\naccrediting at the postsecondary level, applying its criteria for granting\naccreditation in a fair, consistent, and nondiscriminatory manner, such as an\nagency recognized for these purposes by the United States Department of\n\nEducation. (5)\n\nEducation\n\nReview Committee\nshall mean that committee appointed by the\ncommissioner in consultation with the chancellor of the State University of New\n\nYork, pursuant to subdivision 9 of section\n7101-a\nof the\n\nEducation Law, whose function is to advise and assist the commissioner in\nevaluating acceptable clinical training. (6)\n\nTemporary Evaluation\n\nCommittee\nshall mean that committee appointed by the commissioner of\neducation to advise the commissioner in the evaluation of optometric use of\ntherapeutic pharmaceutical agents, pursuant to section 3 of Chapter 517 of the\n\nLaws of 1995. (b) Certification requirements. (1)\n\nTopical therapeutic pharmaceutical agents and nasal sprays as topical\ntherapeutic pharmaceutical agents for the treatment dry eye disease. To receive\na certificate issued by the department to use topical therapeutic\npharmaceutical agents and nasal sprays as topical therapeutic pharmaceutical\nagents for the treatment dry eye disease, an optometrist shall be licensed in\n\nNew York and meet the clinical training requirements set forth in paragraph (1)\nof subdivision (c) of this section and the examination requirements set forth\nin subdivision (d) of this section. After certification, such topical\ntherapeutic pharmaceutical agents and nasal sprays as topical therapeutic\npharmaceutical agents for the treatment dry eye disease, shall be used in\naccordance with the provisions of Article 143 of the Education Law. (2)\n\nTopical therapeutic pharmaceutical agents\nfor the treatment of glaucoma and ocular hypertension. To receive a certificate\nissued by the department to use topical therapeutic pharmaceutical agents for\nthe treatment of glaucoma and ocular hypertension, an optometrist shall be\nlicensed in New York and certified in the use of topical therapeutic\npharmaceutical agents, as set forth in paragraph (1) of this subdivision, and\nmeet the clinical training requirements set forth in paragraph (2) of\nsubdivision (c) of this section and the examination requirements set forth in\nsubdivision (d) of this section. After certification, such topical therapeutic\npharmaceutical agents for the treatment of glaucoma and ocular hypertension\nshall be used in accordance with the provisions of Article 143 of the Education\n\nLaw. (3)\n\nOral therapeutic\npharmaceutical agents solely for the treatment of diseases of the eye and\nadnexa. To receive a certificate issued by the Department to use oral\ntherapeutic pharmaceutical agents, an optometrist shall be licensed in New York\nand certified in the use of diagnostic drugs as set forth in subdivision (b) of\nsection\n66.4\nof this part, topical\ntherapeutic pharmaceutical agents as set forth in paragraph (1) of this\nsubdivision, and topical therapeutic pharmaceutical agents for the treatment of\nglaucoma and ocular hypertension as set forth in paragraph (2) of this\nsubdivision, and meet the certification course requirements set forth in\nparagraph (3) of subdivision (c) of this section and the examination\nrequirements set forth in subdivision (d) of this section. After certification, such oral therapeutic pharmaceutical agents shall be used in accordance with\nthe provisions of Article 143 of the Education Law. (c) Clinical training and course\nrequirements for certification. (1)\n\nTo\nmeet the clinical training requirements for certification in the use of topical\ntherapeutic pharmaceutical agents and nasal sprays as topical therapeutic\npharmaceutical agents for the treatment dry eye disease, the applicant shall\npresent satisfactory evidence of any of the following: (i) graduation after January 1, 1993 from a\nprofessional program of study in optometry that is registered by the department\npursuant to Part 52 of this Title, or is accredited by an acceptable\naccrediting agency, or determined by the department to be the equivalent of\nsuch a registered or accredited program; or\n(ii)\ngraduation on or before January 1, 1993\nfrom a professional program of study in optometry that is registered by the\ndepartment pursuant to Part 52 of this Title, or is accredited by an acceptable\naccrediting agency, or determined by the department to be the equivalent of\nsuch a registered or accredited program; and completion of at least 300 hours\nof acceptable clinical training, as prescribed in subdivision 4(a) and 9-a of\nsection\n7101-a\nof the\n\nEducation Law; or\n(iii)\ncertification to use topical therapeutic pharmaceutical agents and nasal sprays\nas topical therapeutic pharmaceutical agents for the treatment dry eye disease\nin another jurisdiction, provided that such optometrist has been certified for\nat least five years to use topical therapeutic pharmaceutical agents and nasal\nsprays as topical therapeutic pharmaceutical agents for the treatment dry eye\ndisease in another jurisdiction during which time such use was demonstrated in\nindependently managed patients, meaning that the optometrist demonstrated that\nhe or she has treated patients with topical therapeutic pharmaceutical agents\nand nasal sprays as topical therapeutic pharmaceutical agents for the treatment\ndry eye disease without consultation with a licensed\nphysician. (2)\n\nTo meet the\nclinical training requirements for certification in the use of topical\ntherapeutic pharmaceutical agents for the treatment of glaucoma and ocular\nhypertension, the applicant shall present satisfactory evidence of any of the\nfollowing: (i) Graduation after January 1, 1993 from a professional program of study in optometry that is registered by\nthe department pursuant to Part 52 of this Title, or is accredited by an\nacceptable accrediting agency, or determined by the department to be the\nequivalent of such a registered or accredited program; or\n(ii)\n\nGraduation on or before January 1, 1993\nfrom a professional program of study in optometry that is registered by the\ndepartment pursuant to Part 52 of this Title, or is accredited by an acceptable\naccrediting agency, or determined by the department to be the equivalent of\nsuch a registered or accredited program and completion of at least an\nadditional 100 hours over that obtained for certification to use topical\ntherapeutic pharmaceutical agents of acceptable clinical training, as\nprescribed in subdivisions 4(b) and 9-a of section\n7101-a\nof the\n\nEducation Law; or\n(iii)\n\nCertification to use topical therapeutic pharmaceutical agents for the\ntreatment of glaucoma and ocular hypertension in another jurisdiction, provided\nthat such optometrist has been certified for at least five years to use topical\ntherapeutic agents for the treatment of glaucoma and ocular hypertension in\nanother jurisdiction during which time such use was demonstrated in\nindependently managed patients, meaning that the optometrist demonstrated that\nhe or she has treated patients with topical therapeutic pharmaceutical agents\nfor the treatment of glaucoma and ocular hypertension without consultation with\na licensed physician. (3)\n\nTo meet the course requirements for certification in the use of oral\ntherapeutic pharmaceutical agents, the applicant shall present satisfactory\nevidence of either: (i) graduation after\n\nJanuary 1, 2022 from a professional program of study in optometry that is\nregistered by the department pursuant to part 52 of this Title, or is\naccredited by an acceptable accrediting agency, or determined by the department\nto be the equivalent of such a registered or accredited program, and that the\napplicant has taken and successfully passed the National Board of Examiners in\n\nOptometry examination or an examination acceptable to the Department; or\n(ii)\ngraduation on or before\n\nJanuary 1, 2022 from a professional program of study in optometry that is\nregistered by the department pursuant to Part 52 of this Title, or is\naccredited by an acceptable accrediting agency, or determined by the department\nto be the equivalent of such a registered or accredited program, and that the\napplicant has completed a course of at least 40 hours, as prescribed in\nparagraph (c) of subdivision 4 of section\n7101-a\nof the\n\nEducation Law. (4)\n\nApplicants who meet the clinical training requirements for certification by\ncomplying with the requirements of subparagraph (ii) of paragraph (1) or\nsubparagraph (ii) of paragraph (2) of this subdivision shall submit a written\napplication to the department in a form approved by the department. The\ndepartment shall submit each application to the education review committee for\nits review and recommendation, as prescribed in subdivisions 9 and 9-a of\nsection\n7101-a\nof the\n\nEducation Law. (d) Examination. (1)\n\nTo meet the\nexamination requirement for either certification in the use of topical\ntherapeutic pharmaceutical agents and nasal sprays as topical therapeutic\npharmaceutical agents for the treatment dry eye disease or certification in the\nuse of topical therapeutic pharmaceutical agents for the treatment of glaucoma\nand ocular hypertension the applicant shall present evidence of passing of: (a) the treatment and management of ocular\ndiseases portion of the examination of the National Board of Examiners in\n\nOptometry; or\n(b) an examination\ndetermined by the State Board for Optometry to be equivalent in scope and\ncontent to the ocular diseases portion of the examination of the National Board\nof Examiners in Optometry. (2)\n\nTo meet the examination requirement for\ncertification in the use of oral therapeutic pharmaceutical agents, the\napplicant shall present evidence of passing an examination as prescribed in\nparagraph (c) of subdivision 4 of section\n7101-a\nof the\n\nEducation Law, and which is acceptable to the Department. Provided, however, that pursuant to subparagraph (v) of paragraph (c) of subdivision 4 of section\n7101-a\nof the\n\nEducation Law, such examination requirement shall not apply to applicants who\nmeet the course requirements prescribed in subparagraph (i) or paragraph (3) of\nsubdivision (c) of this section. (e) Reporting requirement. An\noptometrist certified to use topical therapeutic pharmaceutical agents for the\ntreatment of glaucoma and ocular hypertension shall file with the temporary\nevaluation committee a report for each patient treated with topical therapeutic\npharmaceutical agents for the treatment of glaucoma and ocular hypertension\nwithin seven days following the initial and each subsequent visit by the same\npatient. The report shall be in a form developed by the temporary evaluation\ncommittee and approved by the commissioner. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 8\n§\n66.5\n\nAmended\n\nNew\n\nYork State Register June 29, 2022/Volume XLIV, Issue 26, eff. 6/29/2022\n\nAmended\n\nNew\n\nYork State Register February 28, 2024/Volume XLVI, Issue 9, eff. 2/28/2024\n\nAmended\n\nNew\n\nYork State Register June 25, 2025/Volume XLVII, Issue 25, eff. 6/9/2025, exp. 8/7/2025\n(Emergency)\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. (a) Definitions. As used in this section: (1)\n\nTopical therapeutic pharmaceutical agents\nshall mean those drugs identified in paragraph (e) of subdivision (1) of section\n7101-a\nof the Education Law, which shall be limited to topical application to the surface of the eye for therapeutic purposes. (2)\n\nTopical therapeutic pharmaceutical agents for the treatment of glaucoma and ocular hypertension\nshall mean: (i) those drugs identified in paragraph (f) of subdivision (1) of section\n7101-a\nof the Education Law. (3)\n\nOral therapeutic pharmaceutical agents solely for the treatment of diseases of the eye and adnexa\nshall mean those drugs identified in paragraph (g) of subdivision (1) of section\n7101-a\nof the Education Law. (4)\n\nAcceptable accrediting agency\nshall mean an organization accepted by the\ndepartment\nas a reliable authority for the purpose of accrediting at the postsecondary level, applying its criteria for granting accreditation in a fair, consistent, and nondiscriminatory manner, such as an agency recognized for these purposes by the United States\n\nDepartment\nof Education. (5)\n\nEducation Review Committee\nshall mean that committee appointed by the commissioner in consultation with the chancellor of the\n\nState University\nof New York, pursuant to subdivision 9 of section\n7101-a\nof the Education Law, whose function is to advise and assist the commissioner in evaluating acceptable clinical training. (6)\n\nTemporary Evaluation Committee\nshall mean that committee appointed by the commissioner of education to advise the commissioner in the evaluation of optometric use of therapeutic pharmaceutical agents, pursuant to section 3 of Chapter 517 of the Laws of 1995. (b) Certification requirements. (1) Topical therapeutic pharmaceutical agents. To receive a certificate issued by the\ndepartment\nto use topical therapeutic pharmaceutical agents, an optometrist shall be licensed in New York and meet the clinical training requirements set forth in paragraph (1) of subdivision (c) of this section and the examination requirements set forth in subdivision (d) of this section. After certification, such topical therapeutic pharmaceutical agents shall be used in accordance with the provisions of Article 143 of the Education Law. (2) Topical therapeutic pharmaceutical agents for the treatment of glaucoma and ocular hypertension. To receive a certificate issued by the\ndepartment\nto use topical therapeutic pharmaceutical agents for the treatment of glaucoma and ocular hypertension, an optometrist shall be licensed in New York and certified in the use of topical therapeutic pharmaceutical agents, as set forth in paragraph (1) of this subdivision, and meet the clinical training requirements set forth in paragraph (2) of subdivision (c) of this section and the examination requirements set forth in subdivision (d) of this section. After certification, such topical therapeutic pharmaceutical agents for the treatment of glaucoma and ocular hypertension shall be used in accordance with the provisions of Article 143 of the Education Law. (3) Oral therapeutic pharmaceutical agents solely for the treatment of diseases of the eye and adnexa. To receive a certificate issued by the\n\nDepartment\nto use oral therapeutic pharmaceutical agents, an optometrist shall be licensed in New York and certified in the use of diagnostic drugs as set forth in subdivision (b) of section\n66.4\nof this part, topical therapeutic pharmaceutical agents as set forth in paragraph (1) of this subdivision, and topical therapeutic pharmaceutical agents for the treatment of glaucoma and ocular hypertension as set forth in paragraph (2) of this subdivision, and meet the certification course requirements set forth in paragraph (3) of subdivision (c) of this section and the examination requirements set forth in subdivision (d) of this section. After certification, such oral therapeutic pharmaceutical agents shall be used in accordance with the provisions of Article 143 of the Education Law. (c) Clinical training and course requirements for certification. (1) To meet the clinical training requirements for certification in the use of topical therapeutic pharmaceutical agents, the applicant shall present satisfactory evidence of any of the following: (i) graduation after January 1, 1993 from a professional program of study in optometry that is registered by the\ndepartment\npursuant to Part 52 of this Title, or is accredited by an acceptable accrediting agency, or determined by the\ndepartment\nto be the equivalent of such a registered or accredited program; or\n(ii) graduation on or before January 1, 1993 from a professional program of study in optometry that is registered by the\ndepartment\npursuant to Part 52 of this Title, or is accredited by an acceptable accrediting agency, or determined by the\ndepartment\nto be the equivalent of such a registered or accredited program; and completion of at least 300 hours of acceptable clinical training, as prescribed in subdivision 4(a) and 9-a of section\n7101-a\nof the Education Law; or\n(iii) certification to use topical therapeutic pharmaceutical agents in another jurisdiction, provided that such optometrist has been certified for at least five years to use topical therapeutic pharmaceutical agents in another jurisdiction during which time such use was demonstrated in independently managed patients, meaning that the optometrist demonstrated that he or she has treated patients with topical therapeutic pharmaceutical agents without consultation with a licensed physician. (2) To meet the clinical training requirements for certification in the use of topical therapeutic pharmaceutical agents for the treatment of glaucoma and ocular hypertension, the applicant shall present satisfactory evidence of any of the following: (i) Graduation after January 1, 1993 from a professional program of study in optometry that is registered by the\ndepartment\npursuant to Part 52 of this Title, or is accredited by an acceptable accrediting agency, or determined by the\ndepartment\nto be the equivalent of such a registered or accredited program; or\n(ii) Graduation on or before January 1, 1993 from a professional program of study in optometry that is registered by the\ndepartment\npursuant to Part 52 of this Title, or is accredited by an acceptable accrediting agency, or determined by the\ndepartment\nto be the equivalent of such a registered or accredited program and completion of at least an additional 100 hours over that obtained for certification to use topical therapeutic pharmaceutical agents of acceptable clinical training, as prescribed in subdivisions 4(b) and 9-a of section\n7101-a\nof the Education Law; or\n(iii) Certification to use topical therapeutic pharmaceutical agents for the treatment of glaucoma and ocular hypertension in another jurisdiction, provided that such optometrist has been certified for at least five years to use topical therapeutic agents for the treatment of glaucoma and ocular hypertension in another jurisdiction during which time such use was demonstrated in independently managed patients, meaning that the optometrist demonstrated that he or she has treated patients with topical therapeutic pharmaceutical agents for the treatment of glaucoma and ocular hypertension without consultation with a licensed physician. (3) To meet the course requirements for certification in the use of oral therapeutic pharmaceutical agents, the applicant shall present satisfactory evidence of either: (i) graduation after January 1, 2022 from a professional program of study in optometry that is registered by the\ndepartment\npursuant to part 52 of this Title, or is accredited by an acceptable accrediting agency, or determined by the\ndepartment\nto be the equivalent of such a registered or accredited program, and that the applicant has taken and successfully passed the National Board of Examiners in Optometry examination or an examination acceptable to the\n\nDepartment; or\n(ii) graduation on or before January 1, 2022 from a professional program of study in optometry that is registered by the\ndepartment\npursuant to Part 52 of this Title, or is accredited by an acceptable accrediting agency, or determined by the\ndepartment\nto be the equivalent of such a registered or accredited program, and that the applicant has completed a course of at least 40 hours, as prescribed in paragraph (c) of subdivision 4 of section\n7101-a\nof the Education Law. (4) Applicants who meet the clinical training requirements for certification by complying with the requirements of subparagraph (ii) of paragraph (1) or subparagraph (ii) of paragraph (2) of this subdivision shall submit a written application to the\ndepartment\nin a form approved by the\ndepartment. The\ndepartment\nshall submit each application to the education review committee for its review and recommendation, as prescribed in subdivisions 9 and 9-a of section\n7101-a\nof the Education Law. (d) Examination. (1) To meet the examination requirement for either certification in the use of topical therapeutic pharmaceutical agents or certification in the use of topical therapeutic pharmaceutical agents for the treatment of glaucoma and ocular hypertension, the applicant shall present evidence of passing of: (a) the treatment and management of ocular diseases portion of the examination of the National Board of Examiners in Optometry; or\n(b) an examination determined by the State Board for Optometry to be equivalent in scope and content to the ocular diseases portion of the examination of the National Board of Examiners in Optometry. (2) To meet the examination requirement for certification in the use of oral therapeutic pharmaceutical agents, the applicant shall present evidence of passing an examination as prescribed in paragraph (c) of subdivision 4 of section\n7101-a\nof the Education Law, and which is acceptable to the\n\nDepartment. Provided, however, that pursuant to subparagraph (v) of paragraph (c) of subdivision 4 of section\n7101-a\nof the Education Law, such examination requirement shall not apply to applicants who meet the course requirements prescribed in subparagraph (i) or paragraph (3) of subdivision (c) of this section. (e) Reporting requirement. An optometrist certified to use topical therapeutic pharmaceutical agents for the treatment of glaucoma and ocular hypertension shall file with the temporary evaluation committee a report for each patient treated with topical therapeutic pharmaceutical agents for the treatment of glaucoma and ocular hypertension within seven days following the initial and each subsequent visit by the same patient. The report shall be in a form developed by the temporary evaluation committee and approved by the commissioner. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 8\n§\n66.5\n\nAmended\n\nNew York State Register June 29, 2022/Volume XLIV, Issue 26, eff. 6/29/2022\n\nAmended\n\nNew York State Register February 28, 2024/Volume XLVI, Issue 9, eff. 2/28/2024",
  "url_type": "regulation",
  "source_index": 6661
}